Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | TGW101 + TRG001 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| TGW101 | TGW-101|TGW 101 | TGW101 is an antibody-drug conjugate (ADC) containing a click-cleavable diabody targeting TAG72 linked to MMAE, which potentially inhibits tumor growth (Cancer Res (2025) 85 (8_Supplement_1): 1794). | ||
| TRG001 | TRG-001|TRG 001 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06959706 | Phase I | TGW101 + TRG001 | Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors | Recruiting | USA | 0 |